TABLE 1 2008 COMMUNITY PRESCRIPTION NUMBERS, TOGETHER WITH GOVERNMENT AND PATIENT COSTS FOR PBS-LISTED DRUGS Table 1 includes an estimate of community prescription numbers for the 2008 calendar year, costs (government and patient contribution) for the items with a four digit PBS/RPBS code, together with the defined daily dose (DDD) where assigned. There is no cost information available for items with a five digit Amfac drug code. Table 1 excludes the presentation of information on any item with an estimated community use of less than 110 prescriptions in 2008. The prescription items are arranged by ATC code on generic name, and by form and strength using either the PBS drug code (4 digit plus alpha) or, for non-PBS items, the Amfac drug code (5 digit). Note that in this edition, “Item type” has been added to distinguish between PBS drug code and non-PBS drug code, for instance, P refers to PBS drug code and A refers to Amfac drug code. Note that Anatomical Therapeutic Chemical (ATC) classification index with Defined Daily Doses (DDDs) 2009 is used in all statistics published in this edition (refer to WHO collaborating Centre for Drug Statistics Methodology, ATC classification index with DDDs 2009). An index by 2nd level of the ATC classification follows: ALIMENTARY TRACT AND METABOLISM PAGE NO A01 STOMATOLOGICAL PREPARATIONS 41 A02 DRUGS FOR ACID RELATED DISORDERS 42 A03 DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS 44 A04 ANTIEMETICS AND ANTINAUSEANTS 45 A05 BILE AND LIVER THERAPY 46 A06 LAXATIVES 47 A07 ANTIDIARRHOEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVES 49 A08 ANTIOBESITY PREPARATIONS, EXCLUDING DIET PRODUCTS 51 A09 DIGESTIVES, INCLUDING ENZYMES 52 37 A10 DRUGS USED IN DIABETES 53 A11 VITAMINS 56 A12 MINERAL SUPPLEMENTS 57 A14 ANABOLIC AGENTS FOR SYSTEMIC USE 58 BLOOD AND BLOOD FORMING ORGANS B01 ANTITHROMBOTIC AGENTS 59 B02 ANTIHAEMORRHAGICS 61 B03 ANTIANAEMIC PREPARATIONS 62 B05 BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS 64 B06 OTHER HAEMATOLOGICAL AGENTS 65 CARDIOVASCULAR SYSTEM C01 CARDIAC THERAPY 66 C02 ANTIHYPERTENSIVES 68 C03 DIURETICS 69 C04 PERIPHERAL VASODILATORS 71 C05 VASOPROTECTIVES 72 C07 BETA BLOCKING AGENTS 73 C08 CALCIUM CHANNEL BLOCKERS 74 C09 AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM 76 C10 LIPID MODIFYING AGENTS 79 DERMATOLOGICALS D01 ANTIFUNGALS FOR DERMATOLOGICAL USE 82 D02 EMOLLIENTS AND PROTECTIVES 83 D03 PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS 84 D04 ANTIPRURITICS, INCLUDING ANTIHISTAMINES, ANAESTHETICS ETC 85 D05 ANTIPSORIATICS 86 D06 ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE 87 D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS 88 D08 ANTISEPTICS AND DISINFECTANTS 91 D09 MEDICATED DRESSINGS 92 D10 ANTI-ACNE PREPARATIONS 93 D11 OTHER DERMATOLOGICAL PREPARATIONS 94 38 GENITOURINARY SYSTEM AND SEX HORMONES G01 GYNAECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS 95 G02 OTHER GYNAECOLOGICALS 96 G03 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM 97 G04 UROLOGICALS 103 SYSTEMIC HORMONAL PREpaRATIONS, EXCLUDING SEX HORMONES H01 PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES 105 H02 CORTICOSTEROIDS FOR SYSTEMIC USE 106 H03 THYROID THERAPY 107 H04 PANCREATIC HORMONES 108 H05 CALCIUM HOMEOSTASIS 109 GENERAL ANTIINFECTIVES FOR SYSTEMIC USE J01 ANTIBACTERIALS FOR SYSTEMIC USE 110 J02 ANTIMYCOTICS FOR SYSTEMIC USE 118 J04 ANTIMYCOBACTERIALS 119 J05 ANTIVIRALS FOR SYSTEMIC USE 120 J07 VACCINES 122 ANTINEOPLASTIC AND IMMUNO-MODULATING AGENTS L01 ANTINEOPLASTIC AGENTS 125 L02 ENDOCRINE THERAPY 132 L03 IMMUNOSTIMULANTS 134 L04 IMMUNOSUPPRESSANTS 135 MUSCULO-SKELETAL SYSTEM M01 ANTI-INFLAMMATORY AND ANTI-RHEUMATIC PRODUCTS 138 M02 TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN 141 M03 MUSCLE RELAXANTS 142 M04 ANTI-GOUT PREPARATIONS 143 M05 DRUGS FOR TREATMENT OF BONE DISEASES 144 NERVOUS SYSTEM N01 ANAESTHETICS 145 N02 ANALGESICS 146 N03 ANTI-EPILEPTICS 152 39 N04 ANTI-PARKINSON DRUGS 155 N05 PSYCHOLEPTICS 157 N06 PSYCHOANALEPTICS 163 N07 OTHER NERVOUS SYSTEM DRUGS 167 ANTI-paRASITIC PRODUCTS, INSECTICIDES AND REPELLENTS P01 ANTI-PROTOZOALS 169 P02 ANTHELMINTICS 170 P03 ECTOPARASITICIDES, INCLUDING SCABICIDES, INSECTICIDES AND REPELLENTS 171 RESPIRATORY SYSTEM R01 NASAL PREPARATIONS 172 R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES 175 R05 COUGH AND COLD PREPARATIONS 178 R06 ANTI-HISTAMINES FOR SYSTEMIC USE 180 SENSORY ORGANS S01 OPHTHALMOLOGICALS 184 S02 OTOLOGICALS 190 S03 OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS 191 VaRIOUS V01 ALLERGENS 192 V03 ALL OTHER THERAPEUTIC PRODUCTS 193 40 A 2008 ATC ITEM TYPE CODe FORM AND STRENGTH DDD UNITS SCRIPTS Cost($) ALIMENTARY TRACT AND METABOLISM STOMATOLOGICAL PREPARATIONS STOMATOLOGICAL PREPARATIONS ANTIINFECTIVES FOR LOCAL ORAL TREATMENT A01AB04 AMPHOTERICIN P 2931G Lozenge 10mg 40.00 MG 160,670 1,603,103 P 3306B Lozenge 10mg 40.00 MG 4,565 44,464 A01AB03 CHLORHEXIDINE P 4161B Mouth wash 2mg per mL (0.2%) 250mL 30.00 MG 2,789 34,058 A01AB09 MICONAZOLE A 13832 Oral gel 20mg per mL (2%) 20g 0.20 GM 3,039 – A 14054 Oral gel 40mg per mL (2%) 40g 0.20 GM 2,719 – A01AB11 NYSTATIN P 3033P Oral suspension 100,000 units per mL 24mL 1500.00 TE 130,789 1,338,294 P 3343Y Oral suspension 100,000 units per mL 24mL 1500.00 TE 851 8,551 CORTICOSTEROIDS FOR LOCAL ORAL TREATMENT A01AC01 TRIAMCINOLONE ACETONIDE with PECTIN A 11075 Paste 1% 5gm – – 11,508 – OTHER AGENTS FOR LOCAL ORAL TREATMENT A01AD02 BENZYDAMINE HYDROCHLORIDE P 1121B Mouth and throat rinse 22.5mg per 15mL 500mL – – 5,456 107,356 P 5385K Mouth and throat rinse 22.5mg per 15mL 500mL – – 159 3,675 A01AD11 CHOLINE SALICYLATE with CETALKONIUM CHLORIDE A 12855 Gel 10g 1 – – 1,167 – A01AD11 SALIVA SUBSTITUTE P 4568K Solution 25mL – – 474 4,431 P 4569L Solution 100mL – – 586 7,549 A01AD11 VARIOUS P 5334R Spray 10mg per mL 100mL – – 233 4,171 41 A 2008 ATC ITEM TYPE CODe FORM AND STRENGTH DDD UNITS SCRIPTS Cost($) ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS ANTACIDS ALUMINIUM COMPOUNDS A02AB01 ALUMINIUM HYDROXIDE A 10038 Tablet 600mg 100 – – 1,016 – CALCIUM COMPOUNDS A02AC10 CALCIUM CARBONATE with GLYCINE P 4055K Tablet 420mg–180mg – – 279 6,251 COMBS.AND COMPLEXES OF ALUMINIUM,CALCIUM AND MAGNESIUM COMPOUNDS A02AD ALUMINIUM HYDROXIDE with MAGNESIUM HYDROXIDE P 2157M Oral suspension 200mg–200mg per 5mL 500mL – – 81,347 1,201,459 P 2576N Tablet 200mg–200mg – – 40,918 603,239 P 4118R Oral suspension 400mg–400mg–30mg per 5mL – – 2,445 50,808 A02AD01 ALUMINIUM HYDROXIDE with MAGNESIUM HYDROXIDE with SIMETHICONE P 4453J Tablet 400mg–400mg–40mg 200 – – 2,075 92,338 A02AD ALUMINIUM HYDROXIDE with MAGNESIUM TRISILICATE and MAGNESIUM HYDROXIDE P 2159P Oral suspension 250mg–120mg–120mg per 5mL – – 21,561 288,708 DRUGS FOR PEPTIC ULCER AND GORD H2-RECEPTOR ANTAGONISTS A02BA01 CIMETIDINE P 1157X Tablet 200mg 0.80 GM 2,978 63,075 P 1158Y Tablet 400mg 0.80 GM 25,453 544,231 P 1159B Tablet 800mg 0.80 GM 1,962 44,126 A02BA03 FAMOTIDINE P 2487X Tablet 20mg 40.00 MG 60,815 1,124,102 P 2488Y Tablet 40mg 40.00 MG 66,925 1,323,647 A02BA04 NIZATIDINE P 1504E Capsules 300mg 30 0.30 GM 48,517 1,043,319 P 1505F Capsules 150mg 30 0.30 GM 75,599 1,563,916 A02BA02 RANITIDINE HYDROCHLORIDE P 1937Y Effervescent tablet 150mg (base) 0.30 GM 46,190 872,540 P 1977C Tablet 300mg (base) 0.30 GM 264,945 5,171,919 P 1978D Tablet 150mg (base) 0.30 GM 711,934 13,452,288 P 8162N Syrup 150mg (base) per 10mL 300mL 0.30 GM 26,026 494,155 P 8903N Effervescent tablet 150mg (base) 0.30 GM 1,585 37,754 P 8905Q Syrup 150mg (base) per 10mL 300mL 0.30 GM 564 12,940 42 A 2008 ATC ITEM TYPE CODe FORM AND STRENGTH DDD UNITS SCRIPTS Cost($) ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GORD PROSTAGLANDINS A02BB01 MISOPROSTOL P 1648R Tablet 200ug 0.80 MG 2,269 116,531 PROTON PUMP INHIBITORS A02BC05 ESOMEPRAZOLE P 8600P Tablet 20mg (enteric coated) 30 30.00 MG 3,133,127 118,263,365 P 8601Q Tablet 40mg (enteric coated) 30 30.00 MG 2,388,665 141,196,401 P 8886Q Tablet 20mg (enteric coated) 30 30.00 MG 119,269 4,490,387 A02BC03 LANSOPRAZOLE P 2240X Capsule 30mg 30.00 MG 24,841 923,733 P 2241Y Capsule 30mg 30.00 MG 744,635 30,432,338 P 8198L Capsule 15mg 30.00 MG 20,583 492,637 P 8528W Sachet for oral suspension 30mg 30.00 MG 2,594 96,298 P 8529X Sachet for oral suspension 30mg 30.00 MG 18,213 708,550 P 8950C Sachet for oral suspension 30mg 28 30.00 MG 1,349 70,241 A02BC01 OMEPRAZOLE P 1326T Capsule 20mg 20.00 MG 20,112 564,763 P 1327W Capsule 20mg 20.00 MG 224,738 8,364,740 P 8331L Tablet 20mg (as magnesium salt) 30 20.00 MG 20,330 625,532 P 8332M Tablet 10mg (as magnesium salt) 30 20.00 MG 65,596 1,666,424 P 8333N Tablet 20mg (as magnesium salt) 30 20.00 MG 494,288 18,029,427 P 9109K Tablet 20mg (as magnesium salt) 30 20.00 MG 79,559 2,566,476 P 9110L Tablet 20mg (as magnesium salt) 30 20.00 MG 2,753,130 100,886,445 A02BC02 PANTOPRAZOLE A 20489 Tablet (enteric coated) equivalent to 20mg 14 40.00 MG 123 – P 8007K Tablet (enteric coated) equivalent to 40mg 40.00 MG 328,203 12,502,960 P 8008L Tablet (enteric coated) equivalent to 40mg 40.00 MG 2,760,152 112,997,620 P 8399C Tablet (enteric coated) equivalent to 20mg 40.00 MG 311,964 6,867,784 A02BC04 RABEPRAZOLE P 8507R Tablet 10mg 30 20.00 MG 55,354 2,106,994 P 8508T Tablet 20mg 30 20.00 MG 1,840,005 75,134,273 P 8509W Tablet 20mg 30 20.00 MG 229,213 8,609,265 COMBINATIONS FOR ERADICATION OF HELICOBACTER PYLORI A02BD06 ESOMEPRAZOLE AMOXICILAN and CLARITHROMYCIN P 8738X Pack 14 tabs(ent coated)equiv 20mg esomeprazole – – 70,196 6,283,456 A02BD05 OMEPRAZOLE and CLARITHROMYCIN and AMOXYCILLIN P 8272J Pack 14 caps 20mg,14 tabs 500mg,28 caps